IE00B56GVS15
© BusinessWire
06.01.2026
ALKS
LISTED
NASDAQ
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
News Preview
Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), based on phase 1 and phase 2 clinical data, including positive results from Vibrance-1, a large (n=92) phase 2 study evaluating alixorexton in patient...
Themefolio
Profiler
Peergroup
© BusinessWire
30.12.2025
ALKS
LISTED
NASDAQ
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, Jan. 13, 2026 at 10:30 a.m. PST (1:30 p.m. EST/6:30 p.m. GMT). The live webcast may be accessed under the Investo...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2025
ALKS
LISTED
NASDAQ
Alkermes to Participate in Two Upcoming Investor Conferences
News Preview
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences.
8th Annual Evercore Healthcare Conference
Date/Time: Wednesday, Dec. 3, 2025 at 2:10 p.m. ET (7:10 p.m. GMT)
Piper Sandler 37th Annual Healthcare Conference
Date/Time: Thursday, Dec. 4, 2025 at 12:00 p.m. ET (5:00 p.m. GMT)
The liv...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
19.11.2025
ALKS
LISTED
NASDAQ
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
DUBLIN, Nov. 19, 202...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
19.11.2025
ALKS
LISTED
NASDAQ
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
DUBLIN, Nov. 19, 202...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2025
ALKS
LISTED
NASDAQ
Alkermes Response to Avadel Announcement
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.
DUBLIN, Nov. 14, 2025 /PRNewswire/...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2025
ALKS
LISTED
NASDAQ
Alkermes Response to Avadel Announcement
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.
DUBLIN, Nov. 14, 2025 /PRNewswire/...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2025
ALKS
LISTED
NASDAQ
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
News Preview
– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 –
– Alixorexton Met the Study's Dual Primary Endpoints, Demonstrating Statistically S...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2025
ALKS
LISTED
NASDAQ
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
News Preview
– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 –
– Alixorexton Met the Study's Dual Primary Endpoints, Demonstrating Statistically S...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
ALKS
LISTED
NASDAQ
Alkermes to Participate in Two Upcoming Investor Conferences
News Preview
DUBLIN, Nov. 6, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences.
Stifel 2025 Healthcare Conference
Date/Time: Thursday, Nov. 13, 2025 at 2:40 p.m. ET (7:40 p.m. GMT)...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
ALKS
LISTED
NASDAQ
Alkermes to Participate in Two Upcoming Investor Conferences
News Preview
DUBLIN, Nov. 6, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences.
Stifel 2025 Healthcare Conference
Date/Time: Thursday, Nov. 13, 2025 at 2:40 p.m. ET (7:40 p.m. GMT)...
Themefolio
Profiler
Peergroup
© PR Newswire
28.10.2025
ALKS
LISTED
NASDAQ
Alkermes plc Reports Third Quarter 2025 Financial Results
News Preview
— Third Quarter Revenues of $394.2 Million —
— GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49 —
— Company Raises 2025 Financial Expectations —
DUBLIN, Oct. 28, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported fi...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
28.10.2025
ALKS
LISTED
NASDAQ
Alkermes plc Reports Third Quarter 2025 Financial Results
News Preview
— Third Quarter Revenues of $394.2 Million —
— GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49 —
— Company Raises 2025 Financial Expectations —
DUBLIN, Oct. 28, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported fi...
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2025
ALKS
LISTED
NASDAQ
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION...
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2025
ALKS
LISTED
NASDAQ
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ALKS
LISTED
NASDAQ
Alkermes to Report Third Quarter Financial Results on October 28, 2025
News Preview
DUBLIN, Oct. 20, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Thursday, Oct. 23, 2025 to discuss the company's third quarter financial results.
The webcast player and accompanying slides may be accessed on...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ALKS
LISTED
NASDAQ
Alkermes to Report Third Quarter Financial Results on October 28, 2025
News Preview
DUBLIN, Oct. 20, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Tuesday, Oct. 28, 2025 to discuss the company's third quarter financial results.
The webcast player and accompanying slides may be accessed on...
Themefolio
Profiler
Peergroup
© PR Newswire
12.09.2025
ALKS
LISTED
NASDAQ
Alkermes Appoints Joshua Reed as Chief Financial Officer
News Preview
DUBLIN, Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Mr. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company's management committee.
"I'm delighted to be joining Alker...
Themefolio
Profiler
Peergroup
© PR Newswire
12.09.2025
ALKS
LISTED
NASDAQ
Alkermes Appoints Joshua Reed as Chief Financial Officer
News Preview
DUBLIN, Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Mr. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company's management committee.
"I'm delighted to be joining Alke...
Themefolio
Profiler
Peergroup
© PR Newswire
11.09.2025
ALKS
LISTED
NASDAQ
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
News Preview
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project —
— Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Disorder and/or Schizophrenia —
— Application Period to Run From Sept. 15, 2025 Through Dec. 15, 2025 —
DUBLIN, Sept. 11, 2025 /PRNewswire/ -- Alkermes plc (Nasda...
Themefolio
Profiler
Peergroup
© PR Newswire
11.09.2025
ALKS
LISTED
NASDAQ
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
News Preview
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project —
— Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Disorder and/or Schizophrenia —
— Application Period to Run From Sept. 15, 2025 Through Dec. 15, 2025 —
DUBLIN, Sept. 11, 2025 /PRNewswire/ -- Alkermes plc (Nasda...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ALKS
LISTED
NASDAQ
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
News Preview
– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses –
– Alixorexton Was Generally Well Tolerated at All Doses Tested –
– Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET –
DUBLIN, Sept. 8...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ALKS
LISTED
NASDAQ
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
News Preview
– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses –
– Alixorexton Was Generally Well Tolerated at All Doses Tested –
– Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET –
DUBLIN, Sept....
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ALKS
LISTED
NASDAQ
Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025
News Preview
– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition –
– Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET –
DUBLIN, Aug. 25, 2025 /PRNewswire/ -- Alkermes pl...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ALKS
LISTED
NASDAQ
Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025
News Preview
– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition –
– Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET –
DUBLIN, Aug. 25, 2025 /PRNewswire/ -- Alkermes pl...
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
ALKS
LISTED
NASDAQ
Alkermes plc Reports Second Quarter 2025 Financial Results
News Preview
— Second Quarter Revenues of $390.7 Million —
— GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 —
— Company Reiterates 2025 Financial Expectations —
— Alkermes to Present Detailed Vibrance-1 Results at Upcoming World Sleep Congress —
DUBLIN, July 29, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today...
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
ALKS
LISTED
NASDAQ
Alkermes plc Reports Second Quarter 2025 Financial Results
News Preview
— Second Quarter Revenues of $390.7 Million —
— GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 —
— Company Reiterates 2025 Financial Expectations —
— Alkermes to Present Detailed Vibrance-1 Results at Upcoming World Sleep Congress —
DUBLIN, July 29, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today...
Themefolio
Profiler
Peergroup
© PR Newswire
21.07.2025
ALKS
LISTED
NASDAQ
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1
News Preview
– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 –
– Alixorexton Demonstrated Robust and Consistent Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition at All Doses Tested –...
Themefolio
Profiler
Peergroup
© PR Newswire
21.07.2025
ALKS
LISTED
NASDAQ
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1
News Preview
– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 –
– Alixorexton Demonstrated Robust and Consistent Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition at All Doses Tested –...
Themefolio
Profiler
Peergroup
© PR Newswire
15.07.2025
ALKS
LISTED
NASDAQ
Alkermes to Report Second Quarter Financial Results on July 29, 2025
News Preview
DUBLIN, July 15, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 29, 2025 to discuss the company's second quarter financial results.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www....
Themefolio
Profiler
Peergroup
© PR Newswire
15.07.2025
ALKS
LISTED
NASDAQ
Alkermes to Report Second Quarter Financial Results on July 29, 2025
News Preview
DUBLIN, July 15, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 29, 2025 to discuss the company's second quarter financial results.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
ALKS
LISTED
NASDAQ
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
News Preview
DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
ALKS
LISTED
NASDAQ
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
News Preview
DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
ALKS
LISTED
NASDAQ
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
News Preview
– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles –
DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring, including presentations large...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
ALKS
LISTED
NASDAQ
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
News Preview
– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles –
DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring, including presentations large...
Themefolio
Profiler
Peergroup
© PR Newswire
29.05.2025
ALKS
LISTED
NASDAQ
Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025
News Preview
– Company to Present Eight Posters and Two Oral Presentations, Including New Analyses From ALKS 2680 Phase 1 Study –
– New Research Evaluating the Clinical, Economic and Humanistic Burden of Narcolepsy and Findings From In-Depth Qualitative Patient Interviews on the Burden of Idiopathic Hypersomnia Will Also Be Presented –
DUBLIN, May 29, 2025 /...
Themefolio
Profiler
Peergroup
© PR Newswire
29.05.2025
ALKS
LISTED
NASDAQ
Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025
News Preview
– Company to Present Eight Posters and Two Oral Presentations, Including New Analyses From ALKS 2680 Phase 1 Study –
– New Research Evaluating the Clinical, Economic and Humanistic Burden of Narcolepsy and Findings From In-Depth Qualitative Patient Interviews on the Burden of Idiopathic Hypersomnia Will Also Be Presented –
DUBLIN, May 29, 2025 /...
Themefolio
Profiler
Peergroup
© PR Newswire
01.05.2025
ALKS
LISTED
NASDAQ
Alkermes plc Reports First Quarter 2025 Financial Results
News Preview
— First Quarter Revenues of $306.5 Million —
— GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 —
— Company Reiterates 2025 Financial Expectations —
DUBLIN, May 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2025.
"Our first quarter financial perf...
Themefolio
Profiler
Peergroup
© PR Newswire
01.05.2025
ALKS
LISTED
NASDAQ
Alkermes plc Reports First Quarter 2025 Financial Results
News Preview
— First Quarter Revenues of $306.5 Million —
— GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 —
— Company Reiterates 2025 Financial Expectations —
DUBLIN, May 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2025.
"Our first quarter financial per...
Themefolio
Profiler
Peergroup
© PR Newswire
30.04.2025
ALKS
LISTED
NASDAQ
New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)
News Preview
– Survey Respondents Reported That AUD Diagnosis and Decision to Seek Treatment Were Driven by Negative Consequences of Drinking –
– Respondents Cited the Influence of Their Healthcare Providers and the Positive Impact of Treatment on Their Lives –
DUBLIN, April 30, 2025 /PRNewswire/ -- A new online survey conducted by The Harris Poll on behalf...
Themefolio
Profiler
Peergroup
© PR Newswire
30.04.2025
ALKS
LISTED
NASDAQ
New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)
News Preview
– Survey Respondents Reported That AUD Diagnosis and Decision to Seek Treatment Were Driven by Negative Consequences of Drinking –
– Respondents Cited the Influence of Their Healthcare Providers and the Positive Impact of Treatment on Their Lives –
DUBLIN, April 30, 2025 /PRNewswire/ -- A new online survey conducted by The Harris Poll on behalf...
Themefolio
Profiler
Peergroup
© PR Newswire
17.04.2025
ALKS
LISTED
NASDAQ
Alkermes to Report First Quarter Financial Results on May 1, 2025
News Preview
DUBLIN, April 17, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, May 1, 2025 to discuss the company's first quarter financial results.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www....
Themefolio
Profiler
Peergroup
© PR Newswire
17.04.2025
ALKS
LISTED
NASDAQ
Alkermes to Report First Quarter Financial Results on May 1, 2025
News Preview
DUBLIN, April 17, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, May 1, 2025 to discuss the company's first quarter financial results.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www....
Themefolio
Profiler
Peergroup
© PR Newswire
02.04.2025
ALKS
LISTED
NASDAQ
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
News Preview
DUBLIN, April 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 11:45 a.m. EDT (4:45 p.m. BST). The live...
Themefolio
Profiler
Peergroup
© PR Newswire
02.04.2025
ALKS
LISTED
NASDAQ
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
News Preview
DUBLIN, April 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 11:45 a.m. EDT (4:45 p.m. BST). The live...
Themefolio
Profiler
Peergroup
© PR Newswire
01.04.2025
ALKS
LISTED
NASDAQ
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
News Preview
DUBLIN, April 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic hypersomnia (IH). ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist...
Themefolio
Profiler
Peergroup
© PR Newswire
01.04.2025
ALKS
LISTED
NASDAQ
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
News Preview
DUBLIN, April 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic hypersomnia (IH). ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist...
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
ALKS
LISTED
NASDAQ
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder
News Preview
– Survey Respondents Reported That Medication Adherence is a Top Concern for Healthcare Providers When Selecting Treatments and Frequent Medication Switches Can Have Significant Impacts on Patients' Experiences and Quality of Life –
– 98% of Respondents Agreed* That Quality of Life for a Patient is Just as Important as Symptom Management When Thi...
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
ALKS
LISTED
NASDAQ
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder
News Preview
– Survey Respondents Reported That Medication Adherence is a Top Concern for Healthcare Providers When Selecting Treatments and Frequent Medication Switches Can Have Significant Impacts on Patients' Experiences and Quality of Life –
– 98% of Respondents Agreed* That Quality of Life for a Patient is Just as Important as Symptom Management When Thi...
Themefolio
Profiler
Peergroup
© PR Newswire
26.02.2025
ALKS
LISTED
NASDAQ
Alkermes to Participate in Upcoming Investor Conferences
News Preview
DUBLIN, Feb. 26, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences.
TD Cowen 45th Annual Health Care ConferenceDate/Time: Wednesday, March 5, 2025 at 9:50 a.m. ET (2:50 p.m. GMT)
Leerink Partners Global Healthcare Conference 2025Date/Tim...
Themefolio
Profiler
Peergroup
© PR Newswire
26.02.2025
ALKS
LISTED
NASDAQ
Alkermes to Participate in Upcoming Investor Conferences
News Preview
DUBLIN, Feb. 26, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences.
TD Cowen 45th Annual Health Care ConferenceDate/Time: Wednesday, March 5, 2025 at 9:50 a.m. ET (2:50 p.m. GMT)
Leerink Partners Global Healthcare Conference 2025Date/Ti...
Themefolio
Profiler
Peergroup
© PR Newswire
12.02.2025
ALKS
LISTED
NASDAQ
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025
News Preview
— Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year —
— GAAP Net Income from Continuing Operations of $372 Million and Diluted GAAP Earnings per Share from Continuing Operations of $2.20 for 2024 —
— ALKS 2680 Phase 2 Studies in Narcolepsy Type 1 and Type 2 Ongoing With...
Themefolio
Profiler
Peergroup
© PR Newswire
12.02.2025
ALKS
LISTED
NASDAQ
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025
News Preview
— Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year —
— GAAP Net Income from Continuing Operations of $372 Million and Diluted GAAP Earnings per Share from Continuing Operations of $2.20 for 2024 —
— ALKS 2680 Phase 2 Studies in Narcolepsy Type 1 and Type 2 Ongoing With...
Themefolio
Profiler
Peergroup
© PR Newswire
05.02.2025
ALKS
LISTED
NASDAQ
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025
News Preview
DUBLIN, Feb. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 12, 2025 to discuss the company's fourth quarter and year-end 2024 financial results. Management will also discuss financial expectations for 2025 and provide an update on the com...
Themefolio
Profiler
Peergroup
© PR Newswire
05.02.2025
ALKS
LISTED
NASDAQ
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025
News Preview
DUBLIN, Feb. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 12, 2025 to discuss the company's fourth quarter and year-end 2024 financial results. Management will also discuss financial expectations for 2025 and provide an update on the com...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2025
ALKS
LISTED
NASDAQ
Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
DUBLIN, Jan. 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 15, 2025 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT), followed b...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2025
ALKS
LISTED
NASDAQ
Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
DUBLIN, Jan. 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 15, 2025 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT), followed b...
Themefolio
Profiler
Peergroup
© PR Newswire
25.11.2024
ALKS
LISTED
NASDAQ
Alkermes to Participate in Upcoming Investor Conferences
News Preview
DUBLIN, Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences.
7th Annual Evercore ISI HealthCONx ConferenceDate/Time: Tuesday, Dec. 3, 2024 at 10:25 a.m. ET (3:25 p.m. GMT)
Piper Sandler 36th Annual Healthcare ConferenceDate/Time: Wednesday, Dec. 4, 2024 a...
Themefolio
Profiler
Peergroup
© PR Newswire
25.11.2024
ALKS
LISTED
NASDAQ
Alkermes to Participate in Upcoming Investor Conferences
News Preview
DUBLIN, Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences.
7th Annual Evercore ISI HealthCONx ConferenceDate/Time: Tuesday, Dec. 3, 2024 at 10:25 a.m. ET (3:25 p.m. GMT)
Piper Sandler 36th Annual Healthcare ConferenceDate/Time: Wednesday, Dec. 4, 2024 at...
Themefolio
Profiler
Peergroup
© PR Newswire
11.11.2024
ALKS
LISTED
NASDAQ
Alkermes to Participate in Two Upcoming Investor Conferences
News Preview
DUBLIN, Nov. 11, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate at two upcoming investor conferences.
Stifel Healthcare ConferenceDate/Time: Monday, Nov. 18, 2024 at 8:35 a.m. ET (1:35 p.m. GMT)
Jefferies London Healthcare ConferenceDate/Time: Tuesday, Nov. 19, 2024 at 8:00 a.m. ET (1:00 p.m. GMT...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
